Markets:

Overview

News

Currencies

International

Treasuries

Xeris Biopharma Holdings, Inc. - Common Stock (NQ:XERS)

7.030 -0.010 (-0.14%)

Streaming Delayed Price Updated: 1:24 PM EST, Nov 25, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Xeris Biopharma Holdings, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

The Week Ahead In Biotech (Jan. 2-Jan. 8): Stray Clinical Readouts In Focus In Slow News Week ↗

January 02, 2022

Biotech stocks came under selling pressure in the final week of 2021, although they carved out modest gains for the year. Here are the key catalysts that can sway biotech stocks in the unfolding week.

Via Talk Markets

Attention Biotech Investors: Mark Your Calendar For January PDUFA Dates ↗

December 31, 2021

Regulatory decisions by the U.S. Food and Drug Administration in December turned out to be mostly positive. Among the treatment options that were greenlighted in the month were...

Via Benzinga

Mid-Afternoon Market Update: Dow Rises 50 Points; Nutriband Shares Spike Higher ↗

December 31, 2021

Toward the end of trading Friday, the Dow traded up 0.14% to 36,449.17 while the NASDAQ fell 0.20% to 15,710.56. The S&P also rose, gaining 0.08% to 4,782.32. The U.S. has the...

Via Benzinga

What 4 Analyst Ratings Have To Say About Xeris Biopharma Holdings ↗

December 31, 2021

Analysts have provided the following ratings for Xeris Biopharma Holdings (NASDAQ:

Via Benzinga

XERS Stock Pops on Huge FDA News. Here’s What to Know. ↗

December 31, 2021

The FDA approved Xeris' Recorlev drug for certain adult patients with Cushing's syndrome, sending XERS stock higher.

Via InvestorPlace

Mid-Day Market Update: Crude Oil Down 1%; Xeris Biopharma Shares Jump ↗

December 31, 2021

Midway through trading Friday, the Dow traded down 0.08% to 36,370.19 while the NASDAQ fell 0.07% to 15,730.21. The S&P also fell, dropping 0.02% to 4,777.65. The U.S. has the...

Via Benzinga

21 Stocks Moving In Friday's Mid-Day Session ↗

December 31, 2021

Gainers Nutriband Inc. (NASDAQ: NTRB) shares jumped 120.2% to $8.61 after the company announced the Korean Intellectual Property Office has fully issued its patent titled "...

Via Benzinga

4 Biggest Price Target Changes For Friday ↗

December 31, 2021

SVB Leerink boosted the price target on Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) from $6 to $8. Xeris Biopharma shares rose 18.9% to $2.89 in pre-market trading....

Via Benzinga

Why Xeris Biopharma Shares Are Rising Today ↗

December 31, 2021

Xeris Biopharma Holdings Inc (NASDAQ: XERS) is trading higher Friday morning after the company announced U.S. Food and Drug Administration approval of Recorlev for the...

Via Benzinga

18 Stocks Moving in Friday's Pre-Market Session ↗

December 31, 2021

Gainers Medalist Diversified REIT, Inc. (NASDAQ: MDRR) rose 34.3% to $1.37 in pre-market trading after the company reported a stock repurchase program of 500,000 shares. Xeris...

Via Benzinga

A Peek Into The Markets: US Stock Futures Edge Lower On Final Trading Day Of 2021 ↗

December 31, 2021

Pre-open movers U.S. stock futures traded slightly lower in early pre-market trade on the final trading day of 2021. The Dow Jones dropped around 90 points, snapping a six-session...

Via Benzinga

5 Stocks To Watch For December 31, 2021 ↗

December 31, 2021

Some of the stocks that may grab investor focus today are: Medalist Diversified REIT, Inc. (NASDAQ: MDRR) reported a stock repurchase program of 500,000 shares. Medalist...

Via Benzinga

Xeris Biopharma Announces U.S. FDA Approval of Recorlev® (levoketoconazole) for the Treatment of Endogenous Hypercortisolemia in Adult Patients With Cushing’s Syndrome

December 30, 2021

From Xeris Biopharma Holdings, Inc.

Via Business Wire

5 Beaten Down Biotech Stocks That Could Bounce Big In 2022 ↗

December 27, 2021

Biotech stocks remain poised to eke out modest gains for 2021 after the stellar gains of the previous year. COVID-19 drug and vaccine developers experienced volatility throughout...

Via Benzinga

The Week Ahead In Biotech (Dec.26-Jan. 1): Xeris FDA Decision, Pending Clinical Readouts In Focus In Final Week Of Year ↗

December 26, 2021

Biopharma stocks eked out modest gains in the week ending Dec. 23, with regulatory decisions, clinical readouts and COVID-19 treatment and vaccine developments dictating...

Via Benzinga

Xeris Biopharma Announces the Availability of Ogluo® in the UK Through Its Commercialization Partner, Tetris Pharma

December 16, 2021

From Xeris Biopharma Holdings, Inc.

Via Business Wire

41 Stocks Moving In Monday's Mid-Day Session ↗

November 15, 2021

Gainers Casper Sleep Inc. (NYSE: CSPR) shares climbed 87.1% to $6.64 after the company agreed to be acquired by Durational Capital Management. The company also reported Q3...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For November 17, 2021 ↗

November 17, 2021

Upgrades According to Williams Capital, the prior rating for On Holding AG (NYSE:

Via Benzinga

4 Penny Stocks Insiders Are Buying ↗

November 15, 2021

When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and ...

Via Benzinga

70 Biggest Movers From Yesterday ↗

November 16, 2021

Gainers Casper Sleep Inc. (NYSE: CSPR) shares jumped 88.5% to close at $6.69 on Monday after the company agreed to be acquired by Durational Capital Management. The...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗

November 15, 2021

Welcome back, trader! We're getting right into the thick of it this week with a look at the biggest pre-market stock movers for Monday!

Via InvestorPlace

20 Stocks Moving in Monday's Pre-Market Session ↗

November 15, 2021

Gainers Creative Realities, Inc. (NASDAQ: CREX) rose 132.9% to $3.40 in pre-market trading as the company reported a merger with Reflect Systems on Friday. Bit Brother Limited (...

Via Benzinga

Xeris Biopharma Reports Third Quarter 2021 Financial Results and Other Highlights

November 10, 2021

From Xeris Pharmaceuticals, Inc.

Via Business Wire

Xeris Biopharma to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 10, 2021

November 02, 2021

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Why Xeris Pharmaceuticals Is Soaring 7% Higher Today ↗

October 29, 2021

The biopharma is starting to put together a string of good news advances.

Via The Motley Fool

Benzinga's Top Ratings Upgrades, Downgrades For October 29, 2021 ↗

October 29, 2021

Upgrades For Preferred Bank (NASDAQ:

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

October 25, 2021

Gainers Jaguar Health (NASDAQ:JAGX) shares increased by 14.64% to $2.08 during Monday's regular session. The current volume of 7.2 million shares is 300.39% of Jaguar...

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

October 25, 2021

Gainers Kiromic BioPharma (NASDAQ:KRBP) stock increased by 28.64% to $2.47 during Monday's pre-market session. The company's market cap stands at $38.1 million....

Via Benzinga

Xeris Pharmaceuticals Enters Collaboration Agreement With Merck

October 25, 2021

From Xeris Biopharma Holdings, Inc.

Via Business Wire

The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology ↗

October 12, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 11) AstraZeneca Plc (NASDAQ:...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Oil & Gas Journal starts where other industry publications stop. It delivers more than information; it delivers context, adding details the others leave out and combining them with analysis, commentary, industry trends, and statistics.

Newsletters

The top stories, industry insights and relevant research, assembled by our editors and delivered to your inbox.

Connect

http://www.facebook.com/ogjonline

https://www.linkedin.com/company/oil-&-gas-journal

http://twitter.com/ogjonline

Affiliated Brands

About Us
Advertise
Do Not Sell or Share
Privacy Policy
Terms & Conditions